Abstract:Intravenous iron therapies contain iron–carbohydrate complexes, designed to ensure iron becomes bioavailable via the intermediary of spleen and liver reticuloendothelial macrophages. How other tissues obtain and handle this iron remains unknown. This study addresses this question in the context of the heart. A prospective observational study was conducted in 12 patients receiving ferric carboxymaltose (FCM) for iron deficiency. Myocardial, spleen, and liver magnetic resonance relaxation times and plasma iron markers were collected longitudinally. To examine the handling of iron taken up by the myocardium, intracellular labile iron pool (LIP) was imaged in FCM-treated mice and cells. In patients, myocardial relaxation time T1 dropped maximally 3 h post-FCM, remaining low 42 days later, while splenic T1 dropped maximally at 14 days, recovering by 42 days. In plasma, non-transferrin-bound iron (NTBI) peaked at 3 h, while ferritin peaked at 14 days. Changes in liver T1 diverged among patients. In mice, myocardial LIP rose 1 h and remained elevated 42 days after FCM. In cardiomyocytes, FCM exposure raised LIP rapidly. This was prevented by inhibitors of NTBI transporters T-type and L-type calcium channels and divalent metal transporter 1. Intravenous iron therapy with FCM delivers iron to the myocardium rapidly through NTBI transporters, independently of reticuloendothelial macrophages. This iron remains labile for weeks, reflecting the myocardium's limited iron storage capacity. These findings challenge current notions of how the heart obtains iron from these therapies and highlight the potential for long-term dosing to cause cumulative iron build-up in the heart. In the canonical pathway of intravenous iron metabolism, ferric carboxymaltose (FCM) is taken up by reticuloendothelial macrophages of the spleen and liver. Here, FCM is metabolized and iron liberated for export into the circulation by the iron exporter ferroportin (FPN). Upon export, this iron is loaded onto its plasma chaperone transferrin (Tf). This transferrin-bound iron is then consumed, primarily by the bone marrow for the production of red blood cells (RBCs). Once senescent, RBCs are subjected to breakdown by spleen reticuloendothelial macrophages, allowing this iron to be recycled. Iron may also be stored in hepatocytes, to be mobilized at times of increased iron demand. The heart acquires iron from FCM through a non-canonical pathway that is independent of reticuloendothelial macrophages. This is because FCM releases some of its iron directly into the circulation resulting in the appearance of non-transferrin-bound iron (NTBI). Owing to abundant expression of NTBI transporters L-type and T-type calcium channels (L/TTCC) and divalent metal transporter (DMT1), cardiac myocytes rapidly take up FCM-derived NTBI from the circulation. The iron that enters the cardiac myocytes in this manner joins the intracellular labile iron pool (LIP), which is the pool of reactive iron responsible for generating oxidative stress.

Is myocardial accumulation of non-transferrin-bound iron clinically relevant?

Intravenous iron therapy results in rapid and sustained rise in myocardial iron content through a novel pathway

The clinical relevance of detectable plasma iron species in iron overload states and subsequent to intravenous iron-carbohydrate administration

Might nontransferrin-bound iron in blood plasma and sera be a nonproteinaceous high-molecular-mass FeIII aggregate?

Discordance between biomarkers of iron status in plasma and myocardium across iron replete, iron deficiency, and iron replacement states.

Metal-Ion Transporter SLC39A14 Is Required for Cardiac Iron Loading in the Hjv Mouse Model of Iron Overload

Quantification of cardiac and tissue iron by nuclear magnetic resonance relaxometry in a novel murine thalassemia-cardiac iron overload model

Excess of circulating apo-transferrin enhances dietary iron absorption

Intravenous iron supplementation in heart failure patients induces temporary endothelial dysfunction with release of endothelial microvesicles

Iron imaging in myocardial infarction reperfusion injury

Identification of three mechanistic pathways for iron-deficient heart failure

Quantitative MRI evaluation of iron load in NTDT: Implications for clinical management

Beta-Thalassemia Major and Myocardial Iron Overload: A Longitudinal Study with Magnetic Resonance Imaging

Pre-emptive iron supplementation prevents myocardial iron deficiency and attenuates adverse remodelling after myocardial infarction

PO1-24 HEPATIC CELL-SPECIFIC ATP-BINDING CASSETTE (ABC) TRANSPORTER PROFILING IDENTIFIES PUTATIVE NOVEL CANDIDATES FOR MACROPHAGE CHOLESTEROL HOMEOSTASIS IN MICE

Plasma Non-transferrin-Bound Iron Could Enter into Mice Duodenum and Negatively Affect Duodenal Defense Response to Virus and Immune Responses

MRI-measured Myocardial Iron Load in Patients with Severe Diabetic Heart Failure

Changes in myocardial iron content following administration of intravenous iron (Myocardial‐IRON): Study design

Plasma non-transferrin-bound iron uptake by the small intestine leads to intestinal injury and intestinal flora dysbiosis in an iron overload mouse model and Caco-2 cells

Iron Metabolism in Cardiovascular Disease: Physiology, Mechanisms, and Therapeutic Targets

Iron homeostasis and nutritional iron deficiency